Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Profile of novel topoisomerase II inhibitor, ER-37328, from Eisai

Dec. 11, 1997

Protein farnesyltransferase inhibitors focus of research at Merck & Co.

Dec. 11, 1997

ImClone Systems' C225 enters phase II for metastatic renal cell carcinoma

Dec. 11, 1997

SDZ-PSC-833 increases oral bioavailability of paclitaxel

Dec. 10, 1997

Oncologic Drugs Advisory Committee meets next week

Dec. 10, 1997

Preclinical toxicity profile of ISIS-2503

Dec. 9, 1997

SunPharm's anticancer drug completes phase I

Dec. 8, 1997

IntraBiotics signs manufacturing and supply agreement for IB-367

Dec. 8, 1997

Zeneca selects EGFR-TK inhibitor for clinical evaluation

Dec. 8, 1997

Oncaspar approved in Canada

Dec. 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...